Study of EQU-001 for Uncontrolled Focal Onset Seizures

Focal Onset Seizures Clinical Trial

Official title: A Randomized Phase 2 Study of Adjunctive EQU-001 for Uncontrolled Focal Onset Seizures

Status Terminated

Clinical Trial Summary

This study is a Phase 2 multinational, double-blind, placebo-controlled, randomized (1:1:1), efficacy and safety study of adjunctive EQU-001 for the treatment of focal onset seizures in subjects aged 18 to 65 years, who have been diagnosed with epilepsy according to International League Against Epilepsy (ILAE) Classification of the Epilepsies 2017 criteria This study is designed to test the efficacy and safety of EQU-001 20 mg and 60 mg as compared with placebo as an add-on anti-seizure medication (ASM) in subjects with uncontrolled focal onset seizures. The treatment portion of the study will be comprised of a 4-week double-blind medication activation period and a 12-week double-blind maintenance period.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Focal Onset Seizures
• Seizures

• NCT number: NCT05473442
• Study type: Interventional
• Source: Equilibre Biopharmaceuticals B.V.
• Status: Terminated
• Phase: Phase 2
• Start date: December 27, 2022
• Completion date: July 1, 2023